NEUROLOGICAL ADVERSE EVENTS FOLLOWING IMMUNIZATION (AEFI) ON HEALTH WORKFORCE OF A SECONDARY REFERRAL HOSPITAL IN SOUTH SULAWESI WHO RECEIVED THE

Authors

  • Lutpyah L Faculty of Medicine, Universitas Sam Ratulangi, Manado, Indonesia
  • Arthur Hendrik Philips Mawuntu Neurology Department, Faculty of Medicine, Universitas Sam Ratulangi, Manado, Indonesia
  • Hamdana H RSUD Andi Makkasau, Parepare, Indonesia
  • Mieke Actrees Hanna Nelly Kembuan Neurology Department, Faculty of Medicine, Universitas Sam Ratulangi, Manado, Indonesia

DOI:

https://doi.org/10.21776/ub.mnj.2023.009.01.6

Keywords:

Neurological AEFI, health workforce, COVID-19 vaccine, South Sulawesi

Abstract

Background: The COVID-19 vaccination can relate to the occurrence of neurological adverse events following immunization (AEFI) that could impact work and daily activities. This problem is particularly important in the health workforce. However, little is known about neurological AEFI among the health workforce working in peripheral facilities.

Objective: To study the neurological AEFIs and their impact among the health workforce who received the COVID-19 vaccination in a secondary referral hospital in South Sulawesi, the Andi Makassau Hospital (Rumah Sakit Umum Daerah Andi Makassau/RSAM).

Methods: The COVID-19 pandemic, we created a questionnaire about neurological AEFIs and their effects which were distributed online using the Google Form application to the health workforce at the RSAM who had received at least one dose of COVID-19 vaccination.

Results: We obtained 97 subjects. There were 78.5% neurological AEFIs with the most reported type being muscle pain (16%). Most neurological AEFIs were experienced by women (84.9%), age group 21-35 years (53.8%), and non-doctors/nurses (60.8%). The significant influencing factors in multivariate analysis were age group 36-45 years (p = 0.04), nursing proffesion (p = 0.005), and non- viral-based baccine type (p = < 0.0001).

Conclusion: Neurological AEFI is commonly found among the health workforce who received the COVID-19 vaccination. However, it only has a little impact on their work and attitudes towards vaccination. This may be because all subjects experienced mild neurological AEFI.

References

Ministry of Health of the Republic of Indonesia. Keputusan Menteri Kesehatan No. HK.01.07/MENKES/4638/2021 Tentang Petunjuk Teknis Pelaksanaan Vaksinasi Dalam Rangka Penanggulangan Pandemi COVID-19; 2021. p. 1–157.

D’Souza G, Dowdy D. What is herd immunity and how can we achieve it with covid-19?; 2021.

Available from: https://www.jhsph.edu/covid-19/articles/achieving-herd-immunity-with-covid19.html

WHO. Vaccine safety basics electronic training (module 3 post-immunization adverse events); 2021. Available from: https://in.vaccine-safety- training.org/classification-of-aefis.html

García-Grimshaw M, Ceballos-Liceaga SE, Hernández-Vanegas LE, et al. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study. Clin Immunol; 2021. 229(January). DOI: 10.1016/J.CLIM.2021.108786

World Health Organization. [Homepage on the internet]. Global manual on surveillance of adverse events following immunization; 2016. Available from: https://apps.who.int/iris/handle/10665/206144

Tran VN, An H, Thanh T, Le A, et al. Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021; 2020. DOI : 10.1016/j.vaccine.2021.09.060.

Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lanset; 2020. 396(10267):1979–1993. DOI: 10.1016/S0140-6736(20)32466-1

Endaryanto A. Mengenal isi vaksin covid-19 dan respons tubuh manusia terhadapnya (fokus pada inactivated sars-cov-2 vaccine); 2021. Available from : https://rsudrsoetomo.jatimprov.go.id/wp-content/uploads/2021/01/dr_anang.pdf

Yanjun Z, Et.al. Immunogenicity and safety of a sars- cov-2 inactivated vaccine in healthy adults aged 18-59 years: Report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial. medRxiv; 2020. DOI : 10.1016/s1473-3099(20)30843-4

Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res; 2020. 288(198114). DOI: 10.1016/j.virusres.2020.198114

Bellavite P. Causality assessment of adverse events following immunization: The problem of multifactorial pathology. F1000 Research; 2020. 9.

DOI: 10.12688/f1000research.22600.2

Handayani S, Fannya P, Nazofah P. faktor yang berhubungan dengan kinerja tenaga kesehatan di rawat inap RSUD Batusangkar. J Endur; 2018. 3(3):440.

DOI :10.22216/jen.v3i3.3005

Shrestha S, Devbhandari RP, Shrestha A, et al. Adverse events following the first dose of ChAdOx1 nCoV-19 (COVISHIELD) vaccine in the first phase of vaccine roll out in Nepal. J Patan Acad Heal Sci; 2021. 8(1):9–17. DOI: 10.3126/jpahs.v8i1.36242

Paris C, Benezit F, Geslin M, et al. Covid-19 vaccine hesitancy among healthcare workers; 2021. (1).

DOI: 10.1016/j.idnow.2021.04.001

Downloads

Published

2022-12-20

How to Cite

L, L., Hendrik Philips Mawuntu, A., H, H., & Actrees Hanna Nelly Kembuan, M. . (2022). NEUROLOGICAL ADVERSE EVENTS FOLLOWING IMMUNIZATION (AEFI) ON HEALTH WORKFORCE OF A SECONDARY REFERRAL HOSPITAL IN SOUTH SULAWESI WHO RECEIVED THE . MNJ (Malang Neurology Journal), 9(1), 28–32. https://doi.org/10.21776/ub.mnj.2023.009.01.6

Issue

Vol. 9 No. 1 (2023): January

Section

Research Article

License

Copyright (c) 2022 MNJ (Malang Neurology Journal)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a
Creative Commons Attribution-NonCommercial 4.0 International License